Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 72Neoplasms 7Neoplasm Metastasis 7Breast Diseases 5Neoplasms by Site 3Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Neoplasm Female 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Low Grade Serous Ovarian Cancer 1Locoregional Recurrence 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Granulosa Cell Ovarian Cancer 1Fallopian Tube Neoplasms 1Endometrial Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1Carcinoma, Ductal, Breast 1Breast Carcinoma In Situ 1

Interventions

palbociclib 1exemestane 1Letrozole 1Hydroxychloroquine 1BID protein, human 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer × Anastrozole × 1 year × Clear all
NCT07061717 2025-07-11

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Not yet recruiting
474 enrolled
Breast

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡